(Q39672429)

13 September 2017

title

Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275 (English)

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1573-3

15 June 2024

1 reference

Annette Altmann

1

1 reference

13 September 2017

Michael Eisenhut

2

1 reference

13 September 2017

Ulrike Bauder-Wüst

3

1 reference

13 September 2017

Annette Markert

4

1 reference

13 September 2017

Vasileios Askoxylakis

5

1 reference

13 September 2017

Holger Hess-Stumpp

6

1 reference

13 September 2017

Uwe Haberkorn

7

1 reference

13 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20680269

15 June 2024

publication date

3 August 2010

1 reference

13 September 2017

number of pages

12

1 reference

full work available at URL

inferred from page(s)

http://link.springer.com/content/pdf/10.1007/s00259-010-1573-3.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1573-3

http://link.springer.com/article/10.1007/s00259-010-1573-3/fulltext.html

15 June 2024

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1573-3

http://link.springer.com/content/pdf/10.1007/s00259-010-1573-3

15 June 2024

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1573-3

European Journal of Nuclear Medicine and Molecular Imaging

15 June 2024

published in

1 reference

13 September 2017

volume

37

1 reference

13 September 2017

issue

12

1 reference

13 September 2017

page(s)

2286-2297

1 reference

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1573-3

Cell-cycle inhibitors: three families united by a common cause

21 January 2018

1 reference

12 December 2020

Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin

1 reference

12 December 2020

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

12 December 2020

Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine

1 reference

12 December 2020

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

12 December 2020

Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells.

1 reference

12 December 2020

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

1 reference

12 December 2020

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

1 reference

12 December 2020

Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin

1 reference

12 December 2020

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

1 reference

12 December 2020

The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells

1 reference

12 December 2020

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

1 reference

12 December 2020

Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity

1 reference

12 December 2020

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

12 December 2020

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

1 reference

12 December 2020

Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate

1 reference

12 December 2020

1 reference

12 December 2020

Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells

1 reference

12 December 2020

Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways

1 reference

12 December 2020

Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy

1 reference

12 December 2020

Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor

1 reference

12 December 2020

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

12 December 2020

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

12 December 2020

p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage

1 reference

12 December 2020

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

1 reference

12 December 2020

Histone deacetylase inhibitors as new cancer drugs

1 reference

12 December 2020

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

12 December 2020

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

1 reference

12 December 2020

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

1 reference

12 December 2020

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

1 reference

12 December 2020

Role of the histone deacetylase complex in acute promyelocytic leukaemia

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer therapy

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer treatment

1 reference

12 December 2020

Glucose transport and apoptosis after gene therapy with HSV thymidine kinase

1 reference

12 December 2020

Constitutive hyperexpression of p21(WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas.

1 reference

12 December 2020

Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors

1 reference

12 December 2020

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

12 December 2020

Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells

1 reference

12 December 2020

Histone deacetylase inhibitors: Potential in cancer therapy

1 reference

12 December 2020

Molecular Pharmacology

18

60

828

AJ Burgess

2001

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1573-3

Gene therapy & molecular biology

15 June 2024

22

8

61

RK Lindemann

2004

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1573-3

15 June 2024

Identifiers

1 reference

13 September 2017

1 reference